دورية أكاديمية
أعرض في EDS

A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.

التفاصيل البيبلوغرافية
العنوان: A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.
المؤلفون: Fergus IV; Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA, icilma.fergus@mountsinai.org., Connell KL, Ferdinand KC
المصدر: Current cardiology reports [Curr Cardiol Rep] 2015 Jun; Vol. 17 (6), pp. 38.
نوع المنشور: Comparative Study; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Current Science Country of Publication: United States NLM ID: 100888969 Publication Model: Print Cited Medium: Internet ISSN: 1534-3170 (Electronic) Linking ISSN: 15233782 NLM ISO Abbreviation: Curr Cardiol Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Current Science, c1999-
مواضيع طبية MeSH: Adrenergic beta-Antagonists/*therapeutic use , Blood Pressure/*drug effects , Cardiovascular Diseases/*drug therapy , Nebivolol/*therapeutic use , Nitric Oxide/*metabolism , Vasodilator Agents/*therapeutic use, Adrenergic beta-Antagonists/adverse effects ; Clinical Trials as Topic ; Ethnicity ; Humans ; Insulin Resistance ; Obesity ; Practice Guidelines as Topic ; Risk Factors
مستخلص: Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis.
References: Clin Exp Hypertens A. 1989;11(5-6):973-89. (PMID: 2676266)
Am J Med. 1990 Mar;88(3):223-9. (PMID: 1968710)
N Engl J Med. 2001 May 31;344(22):1659-67. (PMID: 11386264)
Postgrad Med. 2012 Mar;124(2):7-15. (PMID: 22437211)
Circulation. 1997 Oct 7;96(7):2197-205. (PMID: 9337190)
J Am Coll Cardiol. 2007 Mar 6;49(9):963-71. (PMID: 17336720)
J Am Coll Cardiol. 2014 Jul 29;64(4):394-402. (PMID: 25060376)
J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. (PMID: 18402913)
J Clin Pharm Ther. 2006 Apr;31(2):153-9. (PMID: 16635049)
J Clin Hypertens (Greenwich). 2011 Sep;13(9):649-53. (PMID: 21896144)
JAMA. 2004 Nov 10;292(18):2227-36. (PMID: 15536109)
Hypertension. 2012 Apr;59(4):893-8. (PMID: 22353614)
JAMA. 2000 Mar 8;283(10):1295-302. (PMID: 10714728)
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. (PMID: 23747642)
Circulation. 2006 Mar 7;113(9):1213-25. (PMID: 16476843)
Vasc Health Risk Manag. 2012;8:151-60. (PMID: 22454559)
Am J Cardiol. 1991 Jan 1;67(1):67-73. (PMID: 1670902)
Am J Cardiol. 2013 Mar 1;111(5):765-9. (PMID: 23290925)
J Cardiovasc Pharmacol. 2010 Sep;56(3):275-81. (PMID: 20571428)
Circulation. 1996 Dec 1;94(11):2817-25. (PMID: 8941107)
J Clin Hypertens (Greenwich). 2009 Dec;11(12):720-5. (PMID: 20021529)
J Clin Hypertens (Greenwich). 2007 Nov;9(11):866-75. (PMID: 17978594)
J Hum Hypertens. 2011 Mar;25(3):196-202. (PMID: 20376076)
Am J Med. 2010 Jul;123(7 Suppl 1):S21-6. (PMID: 20609696)
World J Cardiol. 2014 Jul 26;6(7):517-30. (PMID: 25068013)
J Hypertens. 2013 Jul;31(7):1281-357. (PMID: 23817082)
Br Med J. 1964 Sep 19;2(5411):725-7. (PMID: 14172036)
J Am Coll Cardiol. 2009 Jun 9;53(23):2150-8. (PMID: 19497441)
JAMA. 2014 Feb 5;311(5):507-20. (PMID: 24352797)
Arch Intern Med. 2008 Jan 28;168(2):207-17. (PMID: 18227370)
Curr Med Res Opin. 2011 Apr;27(4):799-807. (PMID: 21306286)
Endocr Pract. 2006 Mar-Apr;12(2):193-222. (PMID: 16718944)
J Clin Hypertens (Greenwich). 2013 Jan;15(1):14-33. (PMID: 23282121)
Circulation. 2000 May 23;101(20):2338-41. (PMID: 10821806)
Ethn Dis. 2003 Fall;13(4):414-28. (PMID: 14632261)
J Clin Hypertens (Greenwich). 2012 Apr;14(4):198-205. (PMID: 22458740)
J Am Soc Hypertens. 2011 May-Jun;5(3):161-5. (PMID: 21251896)
المشرفين على المادة: 0 (Adrenergic beta-Antagonists)
0 (Vasodilator Agents)
030Y90569U (Nebivolol)
31C4KY9ESH (Nitric Oxide)
تواريخ الأحداث: Date Created: 20150423 Date Completed: 20160111 Latest Revision: 20211203
رمز التحديث: 20221213
DOI: 10.1007/s11886-015-0592-x
PMID: 25899656
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-3170
DOI:10.1007/s11886-015-0592-x